The psychopharmacology-molecular biology interface: Exploring the behavioural roles of dopamine receptor subtypes using targeted gene deletion ("knockout")

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 25, Issue 4, 2001, Pages 925-964

  Waddington, John L ^a   Clifford, Jeremiah J ^a   McNamara, Fergal N ^a   Tomiyama, Katsunori ^a,b   Koshikawa, Noriaki ^b   Croke, David T ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b NIHON UNIVERSITY   (Japan)

Author keywords

"Knockout"; Behavioural regulation; D1 like receptors; D2 like receptors; Dopamine; Dopamine receptor subtypes; Targeted gene deletion

Indexed keywords

DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; RECEPTOR SUBTYPE;

BEHAVIOR; GENE DELETION; HUMAN; KNOCKOUT GENE; MOLECULAR BIOLOGY; PHENOTYPE; PSYCHOPHARMACOLOGY; REVIEW;

ANIMALS; GENE DELETION; HUMANS; MICE; MICE, KNOCKOUT; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, DOPAMINE D4;

EID: 0035042853     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(01)00152-X     Document Type: Article

References (128)

1. 3 dopamine receptor gene is associated with hyperactivity in mice
2. 2-like receptor synergism
3. 2 dopamine receptor colocalization in neostriatal neurons
4. 1 receptor antagonist in primate cells and interacts with other receptors
5. 1 antagonist SKF 83959 in bilaterally MPTP-treated rhesus monkeys: Stable therapeutic effects and wearing-off dyskinesia
6. Partial and full dopamine D1 receptor agonists in mice and rats: Relation between behavioural effects and stimulation of adenylate cyclase activity in vitro
7. The selective dopamine D1 receptor agonist A-86929 maintains efficacy with repeated treatment in rodent and primate models of Parkinson's disease
8. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors
9. A behavioural and neuroanatomical assessment of an inbred substrain of 129 mice with behavioural comparisons to C57BL/6J mice
10. 1 receptor from Apis melliferia: Cloning, functional expression, pharmacology, and mRNA localization in the brain
11. 3 receptor agonists
12. 3 knock-out and wild-type mice
13. 3 receptor knock-out mice
14. 4 antagonist PNU-101387G: In vivo effects on mesocortical, mesolimbic, and nigrostriatal dopamine and serotonin release
15. How close are we to implementing gene targeting in animals other than the mouse?
16. 1 receptor subtypes in vertebrates
17. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation
18. 3 dopamine receptor antagonists using an ethologically-based approach
19. 4 dopamine receptor agonists and antagonists
20. 1A dopamine receptor: Paradoxical elevation of grooming syntax
21. 1-like receptor not coupled to adenylyl cyclase
22. 2 dopamine receptor
23. Genetics of mouse behaviour: Interactions with laboratory environment
24. 1A-deficient mouse
25. Behavioural phenotyping of transgenic and knockout mice: Experimental design and evaluation of general health, sensory functions, motor abilities and specific behavioral tests
26. 1A-deficient mutant mice
27. Behavioural evidence for "D-1-like" dopamine receptor subtypes in rat brain using the new isochroman agonist A 68930 and isoquinoline antagonist BW 737C
28. Differential effects of the D1-DA receptor antagonist SCH 39166 on positive and negative symptoms of schizophrenia
29. 1-like" dopamine receptors not linked to adenylyl cyclase
30. 2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum
31. 1 receptor transgenic mice
32. 1A dopamine receptors
33. D1 dopamine receptor-deficient mouse: Cocaine-induced regulation of immediate-early gene and substance P expression in the striatum
34. Dopamine receptors and dopamine transporter in brain function and addictive behaviours: Insights from targeted mouse mutants
35. 1 dopamine receptor neurons by Cre -mediated site-specific recombination
36. Opposite roles of D1 and D5 dopamine receptors in locomotion revealed by selective antisense oligonucleotides
37. 1 receptor gene expression attenuates alcohol-seeking behavior
38. 1 receptor knockout mice
39. Animal models for the negative symptoms of schizophrenia
40. Cloning and functional characterization of a novel dopamine receptor from Drosophila melanogaster
41. Revised nomenclature for strain 129 mice
42. DARPP-32: Regulator of the efficacy of dopaminergic neurotransmission
43. 1A knockout mice
44. 4.4 receptors expressed in CHO cells
45. 44 receptors expressed in HEK293 cells
46. Ethological approaches in behavioral neurogenetic research
47. Targeting genes associated with mammalian behavior: Past mistakes and future solutions
48. Effects of LU-111995 in three models of disrupted prepulse inhibition in rats
49. The broken mouse: The role of development, plasticity and environment in the interpretation of phenotypic changes in knockout mice
50. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter
51. Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset
52. Hierarchical strategy for phenotypic analysis in mice
53. Beyond the dopamine receptor: The DARPP-32/protein phosphatase-1 cascade
54. 1 agonist (ABT-431) on smoked cocaine self-administration in humans
55. 2-like receptors
56. Pharmacologic and behavioral responses of inbred C57BL/6J and strain 129/SvJ mouse lines
57. 4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys
58. Loss of autoreceptor functions in mice lacking the dopamine transporter
59. 3 receptors
60. 3 receptors
61. 1 receptors in vertebrates
62. 3 dopamine receptors
63. NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia
64. Multiple receptors for dopamine
65. Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations
66. Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice
67. 4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia
68. The D3 dopamine receptor: Neurobiology and potential clinical relevance
69. 3 receptors: Relevance for the drug treatment of Parkinson's disease
70. 3 receptors
71. 1A-deficient mutant mice
72. Direct protein-protein coupling enables cross-talk between dopamine D5 and γ-aminobutyric acid A receptors
73. 2+ mobilizatlon in Xenopus oocytes
74. -/- knockout mice
75. 3 dopamine receptor
76. 3 receptor knockdown through antisense oligonucleotide administration supports its inhibitory role in locomotion
77. Loss of autoreceptor function in dopaminergic neurons from dopamine D2 receptor deficient mice
78. 2 receptors
79. Retained cocaine conditioned place preference in D1 receptor deficient mice
80. Dopamine receptors: From structure to function
81. Dopaminergic behaviour stereospecifically promoted by the D-1 agonist R-SK&F 38393 and selectively blocked by the D-1 antagonist SCH 23390
82. 5) receptors in hippocampus
83. 1 dopamine receptor
84. The induction of grooming and vacuous chewing by a series of selective D-1 dopamine receptor agonists: Two directions of D-1:D-2 interaction
85. 1-like dopamine receptors: Molecular biology and pharmacology
86. 4 receptor antagonist, NRA0160: A preclinical neuropharmacological profile
87. Behavioral organization is independent of locomotor activity in 129 and C57 mouse strains
88. 1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets
89. 2 receptors
90. Complications associated with genetic background effects in research using knockout mice
91. Knock-out mouse models used to study neurobiological systems
92. 3 receptor agonist
93. 4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice
94. Agonist-specific coupling of a cloned Drosophila melanogaster D1-like dopamine receptor to multiple second messenger pathways by synthetic agonists
95. 3 receptors in islands of Calleja and shell of nucleus accumbens of the rat: Opposite and synergistic functional interactions
96. Use of SHIRPA and discriminant analysis to characterise marked differences in the behavioural phenotype of six inbred mouse strains
97. Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166)
98. 1 receptor mediates repetitive jaw movements in rats
99. Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine
100. 2 receptor ribozyme inhibits quinpirole-induced stereotypy in rats
101. 3 receptor coexistence
102. Longer, with unique TG splice site, in human brain
103. New insights into dopaminergic receptor function using antisense and genetically altered animals
104. Z
105. 1A dopamine receptors
106. 2A receptor antagonists: LU-111995 and other potential new antipsychotics in development
107. D3 dopamine receptor-deficient mouse: Evidence for reduced anxiety
108. Functional differentiation of multiple dopamine D1-like receptors by NNC 01-0012
109. Feeding behaviour in dopamine-deficient mice
110. 4 receptors: Basic and clinical status
111. 2A antagonist fananserin in the treatment of schizophrenia
112. Dopaminergic behaviors and signal transduction mediated through adenylate cyclase and phospholipase C pathways
113. Evidence for a distinct D1-like dopamine receptor that couples to activation of phosphoinositide metabolism in brain
114. 1 receptor agonists: The way forward for the treatment of Parkinson's disease?
115. Therapeutic potential of selective D-1 dopamine receptor agonists and antagonists in psychiatry and neurology
116. Pre- and postsynaptic D-1 to D-5 dopamine receptor mechanisms in relation to antipsychotic activity
117. Future directions: The clinical significance and therapeutic potential of D-1:D-2 interactions in Parkinson's disease, schizophrenia and other disorders
118. Comparative pharmacology of classical and novel [second-generation] antipsychotics
119. From first-to second generation antipsychotics
120. Levels of functional interaction between "D-1-like" and "D-2-like" dopamine receptor systems
121. Behavioural pharmacology of "D-1-like" dopamine receptors: Further subtyping, new pharmacological probes and interactions with "D-2-like" receptors
122. 1A targeted gene deletion
123. 1A receptor "knock-out"
124. Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses
125. Elimination of cocaine-induced hyperactivity and dopamine-mediated neurophysiological effects in dopamine D1 receptor mutant mice
126. Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors
127. Dopamine D3 receptor mutant and wild-type mice exhibit identical responses to putative D3 receptor-selective agonists and antagonists
128. Behavioral responses to cocaine and amphetamine administration in mice lacking the dopamine D1 receptor